Search Results - "Teft, Wendy A"

A molecular perspective of CTLA-4 function by Teft, Wendy A, Kirchhof, Mark G, Madrenas, Joaquín

“…Within the paradigm of the two-signal model of lymphocyte activation, the interest in costimulation has witnessed a remarkable emergence in the past few years…”
Get full text

Identification and Characterization of Trimethylamine‑N‑oxide Uptake and Efflux Transporters by Teft, Wendy A, Morse, Bridget L, Leake, Brenda F, Wilson, Aze, Mansell, Sara E, Hegele, Robert A, Ho, Richard H, Kim, Richard B

“…Trimethylamine-N-oxide (TMAO) is a recently identified predictor of cardiovascular and chronic kidney disease. TMAO is primarily generated through…”
Get full text

Targeted next generation sequencing as a tool for precision medicine by Gulilat, Markus, Lamb, Tyler, Teft, Wendy A, Wang, Jian, Dron, Jacqueline S, Robinson, John F, Tirona, Rommel G, Hegele, Robert A, Kim, Richard B, Schwarz, Ute I

“…Targeted next-generation sequencing (NGS) enables rapid identification of common and rare genetic variation. The detection of variants contributing to…”
Get full text

Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1) by TEFT, Wendy A, MANSELL, Sara E, KIM, Richard B

“…Tamoxifen is widely prescribed to patients with estrogen receptor-positive breast cancer, and it is a prodrug that requires bioactivation by cytochrome P450…”
Get full text

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events by Wigle, Theodore J., Povitz, Brandi L., Medwid, Samantha, Teft, Wendy A., Legan, Robin M., Lenehan, John, Nevison, Stephanie, Panuganty, Veera, Keller, Denise, Mailloux, Jaymie, Siebring, Victoria, Sarma, Sisira, Choi, Yun‐hee, Welch, Stephen, Winquist, Eric, Schwarz, Ute I., Kim, Richard B.

“…Consensus guidelines exist for genotype‐guided fluoropyrimidine dosing based on variation in the gene dihydropyrimidine dehydrogenase (DPYD). However, these…”
Get full text

Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care by Gulilat, Markus, BMSc, Tang, Anthony, MD, Gryn, Steven E., MD, Leong-Sit, Peter, MD, Skanes, Allan C., MD, Alfonsi, Jeffrey E., MD, Dresser, George K., MD, PhD, Henderson, Sara L., PharmD, Rose, Rhiannon V., MMath, Lizotte, Daniel J., PhD, Teft, Wendy A., PhD, Schwarz, Ute I., MD, PhD, Tirona, Rommel G., PhD, Kim, Richard B., MD

“…Abstract Background Direct-acting oral anticoagulants (DOACs) are widely prescribed for stroke prevention in patients with atrial fibrillation. An important…”
Get full text

Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn’s disease by Wilson, Aze, Almousa, Ahmed, Teft, Wendy A., Kim, Richard B.

“…Bile acids are endogenous ligands of nuclear receptors pregnane X (PXR) and farnesoid X (FXR). PXR and FXR regulate pathways that are impaired in inflammatory…”
Get full text

Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease by Wilson, Aze, Teft, Wendy A., Morse, Bridget L., Choi, Yun-Hee, Woolsey, Sarah, DeGorter, Marianne K., Hegele, Robert A., Tirona, Rommel G., Kim, Richard B.

“…Background The gastrointestinal (GI) microbiome is recognized for potential clinical relevance in inflammatory bowel disease (IBD). Data suggest that there is…”
Get full text

Structure-Function analysis of the CTLA-4 interaction with PP2A by Teft, Wendy A, Chau, Thu A, Madrenas, Joaquín

“…CTLA-4 functions primarily as an inhibitor of T cell activation. There are several candidate explanations as to how CTLA-4 modulates T cell responses, but the…”
Get full text

Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients by Teft, Wendy A., Winquist, Eric, Nichols, Anthony C., Kuruvilla, Sara, Richter, Suzanne, Parker, Christina, Francis, Peggy, Trinnear, Maureen, Lukovic, Jelena, Bukhari, Nedal, Choi, Yun-Hee, Welch, Stephen, Palma, David A., Yoo, John, Kim, Richard B.

“…•Weekly cisplatin dosing reduces cisplatin induced ototoxicity.•MATE1 A/A subjects are at reduced ototoxicity risk.•COMT carriers are at increased risk of…”
Get full text

Food Effect on Rosuvastatin Disposition and Low‐Density Lipoprotein Cholesterol by McLean, Cheynne C., Teft, Wendy A., Morse, Bridget L., Gryn, Steven E., Hegele, Robert A., Kim, Richard B.

“…Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and hepatic transporter‐mediated accumulation in the liver enhances its efficacy…”
Get full text

CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy by Jansen, Laura E., Teft, Wendy A., Rose, Rhiannon V., Lizotte, Daniel J., Kim, Richard B.

“…Purpose Tamoxifen is frequently prescribed to prevent breast cancer recurrence. Tamoxifen is a prodrug and requires bioactivation by CYP2D6. Tamoxifen use is…”
Get full text

Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients by Borrie, Adrienne E., Rose, Finnley A., Choi, Yun-Hee, Perera, Francisco E., Read, Nancy, Sexton, Tracy, Lock, Michael, Vandenberg, Theodore A., Hahn, Karin, Younus, Jawaid, Logan, Diane, Potvin, Kylea, Yaremko, Brian, Yu, Edward, Lenehan, John, Welch, Stephen, Teft, Wendy A., Kim, Richard B.

“…Purpose Female patients with breast cancer frequently develop arthralgia when treated with aromatase inhibitors (AI). Although the mechanism of AI-induced…”
Get full text

Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A422 by Baxter, Simon D., Teft, Wendy A., Choi, Yun-Hee, Winquist, Eric, Kim, Richard B.

“…Tamoxifen use is often limited in some patients due to adverse effects including severe hot flash symptoms. Tamoxifen undergoes hepatic bioactivation by CYP2D6…”
Get full text

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy by Teft, Wendy A., Gong, Inna Y., Dingle, Brian, Potvin, Kylea, Younus, Jawaid, Vandenberg, Theodore A., Brackstone, Muriel, Perera, Francisco E., Choi, Yun-Hee, Zou, Guangyong, Legan, Robin M., Tirona, Rommel G., Kim, Richard B.

“…Tamoxifen is a widely utilized adjuvant anti-estrogen agent for hormone receptor-positive breast cancer, known to undergo CYP2D6-mediated bioactivation to…”
Get full text

Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report by Henderson, Sara L, Teft, Wendy A, Kim, Richard B

“…Tamoxifen, a common anti-estrogen breast cancer medication, is a prodrug that undergoes bioactivation via cytochrome P450 enzymes, CYP2D6 and to a lesser…”
Get full text

Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort by Gryn, Steven E, Teft, Wendy A, Kim, Richard B

“…Tamoxifen is a prodrug, requiring cytochrome P450 enzyme-mediated metabolism to form the active metabolite endoxifen. We identified a case of drug–drug…”
Get full text

Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer by Borrie, Adrienne E., Rose, Rhiannon V., Choi, Yun-Hee, Perera, Francisco E., Read, Nancy, Sexton, Tracy, Lock, Michael, Vandenberg, Theodore A., Hahn, Karin, Dinniwell, Robert, Younus, Jawaid, Logan, Diane, Potvin, Kylea, Yaremko, Brian, Yu, Edward, Lenehan, John, Welch, Stephen, Tyndale, Rachel F., Teft, Wendy A., Kim, Richard B.

“…Purpose The aromatase inhibitor (AI) letrozole is a first-line drug in the adjuvant treatment of breast cancer in postmenopausal women. Adherence to AI…”
Get full text

Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts by Gong, Inna Y., Teft, Wendy A., Ly, Justin, Chen, Yung-Hsiang, Alicke, Bruno, Kim, Richard B., Choo, Edna F.

“…Tamoxifen is a widely prescribed adjuvant anti-estrogen agent for estrogen receptor-positive breast cancer. Tamoxifen is known to undergo CYP2D6-mediated…”
Get full text

Sunny outlook for personalized medicine: tamoxifen and beyond by Teft, Wendy A, Kim, Richard B

Get more information